Sino Biopharmaceutical (SEHK:1177) Could Be 66% Below Fair Value As Earnings Lift Interest

Half year earnings update and why Sino Biopharmaceutical stock is in focus

Sino Biopharmaceutical (SEHK:1177) recently reported half year 2026 earnings, with sales of CNY 19,444.36 million and net income of CNY 3,434.6 million. Earnings per share from continuing operations also edged higher versus a year earlier.

See our latest analysis for Sino Biopharmaceutical.

The latest earnings release appears to have sharpened investor focus on Sino Biopharmaceutical, with the stock posting a 3.80% 1 day share price return and a 17.17% 7 day share price return, although the year to date share price return is still down 12.03% and the 1 year total shareholder return is down 30.28%, while the 3 year total shareholder return is up 95.94%.

If Sino Biopharmaceutical’s recent move has you rethinking healthcare exposure, it can help to compare it with other treatment focused businesses through a curated set of 130 healthcare AI stocks

The recent rebound in Sino Biopharmaceutical after its half-year results still follows a long period of earlier share price declines. Has most of the recovery already played out, or is the upside case only getting started as you now turn to valuation?

Preferred P/E multiple of 35.8x on Sino Biopharmaceutical: Is it justified?

For Sino Biopharmaceutical, the latest check shows the stock trading on a P/E of 35.8x, which is well above both its peer group and the wider Hong Kong Pharmaceuticals industry averages.

The P/E multiple compares the current share price with earnings per share. For a research and development focused pharmaceutical group like Sino Biopharmaceutical, a higher P/E often reflects expectations for future profit growth, the quality of the product portfolio and the perceived resilience of earnings.

In this case, the company is expected to grow earnings by 17.4% per year, which is faster than the Hong Kong market forecast of 11.8% per year. However, the P/E of 35.8x stands above the estimated fair P/E of 21.6x and above the peer average of 16.6x as well as the Hong Kong Pharmaceuticals industry average of 13.6x. This indicates the current multiple embeds a richer earnings outlook than both the fair ratio level the market could move towards and what is currently assigned to sector peers.

Explore the SWS fair ratio for Sino Biopharmaceutical

Result: Price-to-earnings of 35.8x (OVERVALUED)

However, Sino Biopharmaceutical still carries risks, including reliance on Mainland China for all reported revenue and a P/E multiple that already reflects high earnings expectations.

Find out about the key risks to this Sino Biopharmaceutical narrative.

Another view on Sino Biopharmaceutical’s value

The earnings based P/E of 35.8x suggests a rich valuation for Sino Biopharmaceutical, yet the SWS DCF model paints a different picture. On that measure, the stock price of about HK$5.6 sits below an estimated future cash flow value of HK$16.4, which implies a large potential valuation gap. Which signal do you pay more attention to?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Sino Biopharmaceutical for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 269 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mixed signals around Sino Biopharmaceutical can feel confusing, so it is worth checking the underlying numbers, risks and rewards directly. To weigh both sides of the story and see how the key issues balance out, start with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Sino Biopharmaceutical?

If Sino Biopharmaceutical has sharpened your interest in healthcare and valuation, it is worth scanning a broader set of stocks that could fit your portfolio goals.

• Target potential mispricing by running through a focused list of companies that screen as 269 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks that feature 424 dividend fortresses.
• Reduce portfolio stress by concentrating on companies highlighted in our 295 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com